Drug
Proteolytic enzymes
Proteolytic enzymes is a pharmaceutical drug with 2 clinical trials. Historical success rate of 50.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)
Phase Distribution
Ph not_applicable
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
N/A
Trials by Phase
N/A2 (100.0%)
Trials by Status
completed150%
terminated150%
Recent Activity
0 active trials
Showing 2 of 2
completednot_applicable
Manual Therapy and Kinesio Taping on Temporomandibular Joint Dysfunction Following Oral Surgeries
NCT05422703
terminatednot_applicable
Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer
NCT00003851
Clinical Trials (2)
Showing 2 of 2 trials
NCT05422703Not Applicable
Manual Therapy and Kinesio Taping on Temporomandibular Joint Dysfunction Following Oral Surgeries
NCT00003851Not Applicable
Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2